[go: up one dir, main page]

CN114901681A - 胰岛素衍生物 - Google Patents

胰岛素衍生物 Download PDF

Info

Publication number
CN114901681A
CN114901681A CN202080091153.5A CN202080091153A CN114901681A CN 114901681 A CN114901681 A CN 114901681A CN 202080091153 A CN202080091153 A CN 202080091153A CN 114901681 A CN114901681 A CN 114901681A
Authority
CN
China
Prior art keywords
insulin
pharmaceutical composition
acylated insulin
insulin derivatives
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080091153.5A
Other languages
English (en)
Other versions
CN114901681B (zh
Inventor
甘忠如
陈伟
张一宁
薛方凯
蔡玲玉
牛江红
穆彬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Priority to CN202410254314.8A priority Critical patent/CN118420743A/zh
Priority to CN202410288928.8A priority patent/CN118206632A/zh
Priority to CN202410286752.2A priority patent/CN118598978A/zh
Publication of CN114901681A publication Critical patent/CN114901681A/zh
Application granted granted Critical
Publication of CN114901681B publication Critical patent/CN114901681B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

一种酰化胰岛素，其药物制剂、其与长效GLP‑1化合物的药物组合物、及所述酰化胰岛素、药物制剂和药物组合物的医药用途。所述酰化胰岛素相比于德谷胰岛素或其它胰岛素衍生物，具有预料不到的显著增加的药效、具有更长的持续作用时间、更长的体内半衰期、良好的生物利用率、及具有更好的物理稳定性、化学稳定性。

Description

PCT国内申请，说明书已公开。

Claims (55)

  1. PCT国内申请，权利要求书已公开。
CN202080091153.5A 2019-12-30 2020-12-29 胰岛素衍生物 Active CN114901681B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202410254314.8A CN118420743A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410288928.8A CN118206632A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410286752.2A CN118598978A (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019113983780 2019-12-30
CN201911398378 2019-12-30
CN202011057926 2020-09-29
CN2020110579266 2020-09-29
PCT/CN2020/141023 WO2021136296A1 (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202410254314.8A Division CN118420743A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410286752.2A Division CN118598978A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410288928.8A Division CN118206632A (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Publications (2)

Publication Number Publication Date
CN114901681A true CN114901681A (zh) 2022-08-12
CN114901681B CN114901681B (zh) 2024-04-09

Family

ID=76687317

Family Applications (12)

Application Number Title Priority Date Filing Date
CN202411113751.4A Pending CN118772259A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410254905.5A Pending CN118420744A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202080091328.2A Active CN114901683B (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202411112792.1A Pending CN118894922A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202080091153.5A Active CN114901681B (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202080091196.3A Active CN114901682B (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410312576.5A Pending CN118666989A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410286752.2A Pending CN118598978A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410254314.8A Pending CN118420743A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410288928.8A Pending CN118206632A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202411113581.XA Pending CN118754967A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410312489.XA Pending CN118480114A (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CN202411113751.4A Pending CN118772259A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410254905.5A Pending CN118420744A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202080091328.2A Active CN114901683B (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202411112792.1A Pending CN118894922A (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Family Applications After (7)

Application Number Title Priority Date Filing Date
CN202080091196.3A Active CN114901682B (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410312576.5A Pending CN118666989A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410286752.2A Pending CN118598978A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410254314.8A Pending CN118420743A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410288928.8A Pending CN118206632A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202411113581.XA Pending CN118754967A (zh) 2019-12-30 2020-12-29 胰岛素衍生物
CN202410312489.XA Pending CN118480114A (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Country Status (10)

Country Link
US (4) US20230126068A1 (zh)
EP (3) EP4086279A4 (zh)
JP (2) JP2023510219A (zh)
KR (2) KR20220121833A (zh)
CN (12) CN118772259A (zh)
AU (2) AU2020418205A1 (zh)
BR (2) BR112022013009A2 (zh)
CA (2) CA3166494A1 (zh)
MX (2) MX2022008130A (zh)
WO (3) WO2021136302A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3166496A1 (en) * 2019-12-30 2021-07-08 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
AU2022210988B9 (en) 2021-01-20 2023-12-14 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
JP2024521757A (ja) * 2021-05-24 2024-06-04 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 新規なアシル化インスリンアナログ
EP4361174A1 (en) * 2021-06-25 2024-05-01 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin-containing pharmaceutical composition
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN118574842A (zh) * 2022-01-28 2024-08-30 甘李药业股份有限公司 酰化胰岛素
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
WO2024239961A1 (zh) * 2023-05-24 2024-11-28 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用
CN116327890B (zh) * 2023-05-29 2023-12-08 北京先为达生物科技有限公司 口服递送的组合物及其应用
CN116789801B (zh) * 2023-08-21 2023-11-14 南京赛诺生物技术有限公司 新型胰岛素衍生物及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784563A (zh) * 2007-08-15 2010-07-21 诺沃-诺迪斯克有限公司 具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素
CN101842386A (zh) * 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
CN102037008A (zh) * 2008-03-18 2011-04-27 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
US20150111820A1 (en) * 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
WO2017032798A1 (en) * 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
WO2018024186A1 (zh) * 2016-08-02 2018-02-08 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
CN110087674A (zh) * 2016-12-16 2019-08-02 诺和诺德股份有限公司 含胰岛素的药物组合物
US20190345215A1 (en) * 2017-05-26 2019-11-14 Eli Lilly And Company Acylated insulin compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
NZ273285A (en) 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
WO1996034882A1 (en) 1995-05-05 1996-11-07 Eli Lilly And Company Single chain insulin with high bioactivity
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
US20090306337A1 (en) 2006-07-31 2009-12-10 Novo Nordisk A/S Pegylated, Extended Insulins
WO2009010428A1 (en) 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
WO2009022013A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
CN103596584B (zh) * 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
CN104788556A (zh) 2011-12-15 2015-07-22 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
CN105820233B (zh) 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
US20180000742A1 (en) * 2015-01-29 2018-01-04 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating
US10651467B2 (en) * 2015-08-27 2020-05-12 Haldor Topsøe A/S High tap density lithium positive electrode active material, intermediate and process of preparation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784563A (zh) * 2007-08-15 2010-07-21 诺沃-诺迪斯克有限公司 具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素
CN101842386A (zh) * 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
CN102037008A (zh) * 2008-03-18 2011-04-27 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
US20150111820A1 (en) * 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
WO2017032798A1 (en) * 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
WO2018024186A1 (zh) * 2016-08-02 2018-02-08 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
CN110087674A (zh) * 2016-12-16 2019-08-02 诺和诺德股份有限公司 含胰岛素的药物组合物
US20190345215A1 (en) * 2017-05-26 2019-11-14 Eli Lilly And Company Acylated insulin compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
O. ESCRIBANO 等: "The Role of Insulin Receptor Isoforms in Diabetes and Its Metabolic and Vascular Complications", JOURNAL OF DIABETES RESEARCH *
朱尚权 等: "B29-ε-氨基取代的胰岛素衍生物的制备及其受体结合能力", ACTA BIOCHIMICA ET BIOPHYSICA SINICA *

Also Published As

Publication number Publication date
MX2022008174A (es) 2022-08-02
WO2021136296A1 (zh) 2021-07-08
WO2021136302A1 (zh) 2021-07-08
CN118420744A (zh) 2024-08-02
CN114901682B (zh) 2024-04-16
CN118420743A (zh) 2024-08-02
US20240025957A1 (en) 2024-01-25
US20250032589A1 (en) 2025-01-30
EP4086280A4 (en) 2024-05-29
BR112022013150A2 (pt) 2023-02-28
MX2022008130A (es) 2022-10-03
US20230126068A1 (en) 2023-04-27
CN118206632A (zh) 2024-06-18
JP2023510206A (ja) 2023-03-13
CN118598978A (zh) 2024-09-06
CN118666989A (zh) 2024-09-20
CA3166494A1 (en) 2021-07-08
CN118480114A (zh) 2024-08-13
CN114901681B (zh) 2024-04-09
KR20220119730A (ko) 2022-08-30
CN114901683A (zh) 2022-08-12
WO2021136293A1 (zh) 2021-07-08
EP4086279A1 (en) 2022-11-09
AU2020417892A1 (en) 2022-08-25
EP4086278A4 (en) 2024-08-07
EP4086278A1 (en) 2022-11-09
KR20220121833A (ko) 2022-09-01
EP4086280A1 (en) 2022-11-09
CN114901683B (zh) 2024-09-13
BR112022013009A2 (pt) 2022-09-06
CN118754967A (zh) 2024-10-11
JP2023510219A (ja) 2023-03-13
CN114901682A (zh) 2022-08-12
CN118772259A (zh) 2024-10-15
CA3166495A1 (en) 2021-07-08
CN118894922A (zh) 2024-11-05
EP4086279A4 (en) 2024-08-07
AU2020418205A1 (en) 2022-08-04
US20240239862A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
CN114901681A (zh) 胰岛素衍生物
CN111757878A (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
JP2013542247A5 (zh)
CN115916772A (zh) 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
JP2005537234A5 (zh)
JP2005508360A5 (zh)
IL197393A (en) History of pyridine-4-ram, containing and using pharmaceutical preparations for the preparation of drugs for the treatment of immune-related diseases
JO3813B1 (ar) أحماض دهنية جديدة واستخدامها بالاقتران مع جزيئات حيوية
JP2015517488A5 (zh)
RS53056B (en) PHARMACEUTICAL PREPARATION CONTAINING (1S) -1,5-ANHYDRO-1- [5- (4-ETHOXYBENZYL) -2-METHOXY-4-METHYLPHENYL] -1-THI-D-GLUCITOL AND METFORMIN AND ITS USE IN THE TREATMENT OF DIABETES
JP2015057436A5 (zh)
JP2011528896A5 (zh)
JP2009500045A5 (zh)
JP2016510326A5 (zh)
JP2013503165A5 (zh)
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
EA032938B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
JP2015521156A5 (zh)
WO2012090225A3 (en) Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
IL278717B1 (en) Starting dose of pth conjugates
JP2015516419A5 (zh)
JP2015514797A5 (zh)
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
JP2009505991A5 (zh)
WO2015009731A3 (en) Azacyclic constrained analogs of fty720

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant